Randomized trial demonstrates significant improvement in itching and hives with oral remibrutinib in chronic spontaneous urticaria, highlighting its efficacy as an oral targeted therapy.
Treatment with oral remibrutinib resulted in a significant improvement in a composite measure of itching and hives at week 12. (Funded by Novartis Pharmaceuticals; REMIX-1 and REMIX-2 ClinicalTrials.gov numbers, NCT05030311 and NCT05032157, respectively.).
No takes yet. Share an insight, caveat, or question.
Metz et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: